ARIA-E risk of Lilly’s Kisunla in Alzheimer’s reduced with modified dosing
A modified dosing regimen with Eli Lilly’s Alzheimer’s drug Kisunla (donanemab) has shown a reduction in amyloid-related imaging abnormalities with…
Latest News
-
-
J&J and Lilly both unveil IL-23 inhibitor efficacy in Crohn’s disease
Johnson & Johnson (J&J) and Eli Lilly have both revealed the efficacy of their interleukin-23 (IL-23) inhibitors to treat Crohn’s…
-
Kezar Life Sciences discontinues lupus nephritis programme after fatalities
Clinical stage biopharma company Kezar Life Sciences is discontinuing its LN clinical programme following the death of four patients. In…
-
NovoCure scoops FDA approval on wearable for metastatic cancer treatment
NovoCure’s Optune Lua, a wearable indicated for use alongside PD-1/PD-L1 inhibitors (immunotherapy) or docetaxel in adult patients with metastatic non-small…
-
MHRA expects new UK clinical trial regulation implementation by January 2026
The UK’s Medicines and Healthcare products Regulatory Agency (MHRA) expects the new UK clinical trial regulation to be implemented by…
-
Vanqua’s Parkinson’s drug shows promise as company initiates Phase Ib study
Chicago-based Vanqua Bio’s Parkinson’s disease drug has shown proof-of-concept in a first-in-human study. VQ-101 is an oral, small molecule allosteric…
-
FDA gives Adcendo green light to trial ADC in Phase I/II sarcoma study
Adcendo’s antibody-drug conjugate (ADC) candidate will enter a Phase I/II study after receiving Investigational New Drug (IND) clearance from the…
-
Scholar Rock stocks skyrocket after SMA drug scores at Phase III
Scholar Rock’s stock has soared off the back of positive Phase III results from its spinal muscular atrophy (SMA) candidate.…
-
Island Pharmaceuticals trials prevention and therapy benefit of dengue drug
Island Pharmaceuticals has dosed all participants in the first stage of a Phase II trial investigating its dengue fever candidate…
-
Jaguar’s diarrhoea drug shows benefit in Phase III breast cancer subgroup
A diarrhoea drug by Jaguar Health that previously failed in a Phase III oncology trial has shown statistically significant benefit…
